Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDGE-Gastric Phase 2 combination immunotherapy trial in advanced upper GI adenocarcinoma
2021-006291-16Phase 2Active
- Sponsor
- Arcus Biosciences
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of domvanalimab, zimberelimab, quemliclustat in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by Arcus Biosciences. Started Mar 2022; status: active.
02
Drugs
domvanalimabzimberelimabquemliclustat
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2021-006291-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006291-16.